<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00305747</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000462637</org_study_id>
    <secondary_id>P30CA022453</secondary_id>
    <secondary_id>WSU-D-2979</secondary_id>
    <secondary_id>WSU-0507002581</secondary_id>
    <nct_id>NCT00305747</nct_id>
  </id_info>
  <brief_title>Diindolylmethane in Treating Patients With Nonmetastatic Prostate Cancer That Has Not Responded To Previous Hormone Therapy</brief_title>
  <official_title>Phase I Study of Bioresponse-dim in Non-Metastatic, Hormone-Refractory Prostate Cancer Patients With Rising Serum PSA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Barbara Ann Karmanos Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Diindolylmethane may slow the growth of prostate cancer cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of diindolylmethane in&#xD;
      treating patients with nonmetastatic prostate cancer that has not responded to previous&#xD;
      hormone therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Establish the maximum tolerated dose, dose-limiting toxicity, and a recommended phase II&#xD;
           dose of absorption-enhanced diindolylmethane (BioResponse-DIM^® [BR-DIM]) in patients&#xD;
           with nonmetastatic, hormone-refractory prostate cancer and rising serum&#xD;
           prostate-specific antigen (PSA) levels.&#xD;
&#xD;
        -  Evaluate the toxicities of BR-DIM.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Evaluate the plasma pharmacokinetics of twice daily oral administration of BR-DIM in&#xD;
           this patient population.&#xD;
&#xD;
        -  Evaluate the effect of BR-DIM supplementation on serum PSA level.&#xD;
&#xD;
        -  Correlate changes in expression levels of lymphocytes NF-kB with serum PSA levels in&#xD;
           patients taking BR-DIM supplementation.&#xD;
&#xD;
        -  Determine quality of life measures in patients taking BR-DIM supplementation.&#xD;
&#xD;
      OUTLINE: This is an open-label, dose-escalation study.&#xD;
&#xD;
      Patients receive oral absorption-enhanced absorption-enhanced diindolylmethane&#xD;
      (BioResponse-DIM^® [BR-DIM]) twice daily on days 1-28. Treatment repeats every 28 days for up&#xD;
      to 12 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of BR-DIM until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients&#xD;
      experience dose-limiting toxicity. At least 6 patients are treated at the MTD.&#xD;
&#xD;
      Quality of life is assessed at baseline, on day 1 of each course, and at the completion of&#xD;
      study therapy.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 36 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD), Dose limiting toxicity (DLT) &amp; toxicities during study and for 30 days after</measure>
    <time_frame>During study and for 30 days after</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetics as measured by occurrences of toxicity</measure>
    <time_frame>At baseline; Cycle 1 Day 1 at 20, 60, 120, 180, 240, and 480 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum prostate specific antigen as measured by complete plasma concentration-time profile</measure>
    <time_frame>At baseline, Day 1 of each cycle and at study termination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlate changes in expression levels of NF-kB lymphocytes in with serum prostate specific antigen levels by serum prostate specific antigen level</measure>
    <time_frame>At baseline, Cycle 2 and study termination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QOL) by Life Orient. Test-Rev., Duke-UNC Func. Social Support Questionnaire, EORTC QOL questionnaire, QLQ-PR25 questionnaire, and the Hosp. Anxiety &amp; Depression Scale</measure>
    <time_frame>At baseline, day 1 of each cycle and study termination</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>BR-DIM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BR-DIM will be administered at a starting dose of 75 mg po twice daily. Patients will be instructed to take tablets twice daily with 8 ozs. of water, with/without food. A study calendar will be provided and patients will be asked to fill the appropriate boxes when they take their study capsules. One treatment cycle is 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BR-DIM</intervention_name>
    <description>75 mg orally (po) twice daily. May continue treatment for 12 months, however patients will be taken off study if their disease progresses, or have intolerable side effects.</description>
    <arm_group_label>BR-DIM</arm_group_label>
    <other_name>oral microencapsulated diindolylmethane</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven adenocarcinoma of the prostate&#xD;
&#xD;
          -  Prostate specific antigen (PSA)-only failure after local therapy (surgery, radiation&#xD;
             therapy, brachytherapy, or cryotherapy)&#xD;
&#xD;
          -  Rising PSA despite androgen-deprivation therapy with castrate levels of testosterone&#xD;
             (&lt; 50 ng/dL)&#xD;
&#xD;
               -  Two successive rising PSA levels at least 1 week apart&#xD;
&#xD;
               -  PSA ≥ 5 ng/mL&#xD;
&#xD;
          -  Patients with a history of combined hormonal therapy must continue luteinizing-hormone&#xD;
             releasing-hormone agonist treatment but must demonstrate rising PSA after&#xD;
             anti-androgen withdrawal&#xD;
&#xD;
          -  No evidence of distant metastasis by bone scan and CT scan&#xD;
&#xD;
          -  No known brain metastases requiring active therapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status ≤ 3&#xD;
&#xD;
          -  Life expectancy ≥ 12 weeks&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 8.0 g/dL&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGOT and/or SGPT ≤ 2.5 times ULN AND alkaline phosphatase normal OR alkaline&#xD;
             phosphatase ≤ 4 times ULN AND SGOT and/or SGPT normal&#xD;
&#xD;
          -  Creatinine clearance ≥ 60 mL/min OR creatinine normal&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  None of the following conditions within the past 6 months:&#xD;
&#xD;
               -  Myocardial infarction&#xD;
&#xD;
               -  Severe or unstable angina&#xD;
&#xD;
               -  Symptomatic congestive heart failure&#xD;
&#xD;
               -  Cerebrovascular accident or transient ischemic attack&#xD;
&#xD;
               -  Coronary/peripheral artery bypass grafting&#xD;
&#xD;
          -  No other severe acute or chronic medical or psychiatric condition or laboratory&#xD;
             abnormality that would preclude study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 28 days since prior radiotherapy&#xD;
&#xD;
          -  At least 28 days since prior investigational agents for treatment of prostate cancer&#xD;
&#xD;
          -  At least 4 weeks since prior flutamide&#xD;
&#xD;
          -  At least 6 weeks since prior bicalutamide&#xD;
&#xD;
          -  No other concurrent antineoplastic agents&#xD;
&#xD;
          -  No concurrent warfarin-related anticoagulants&#xD;
&#xD;
          -  No concurrent proton-pump inhibitor drugs for gastroesophageal reflux disease (e.g.,&#xD;
             rabeprazole, esomeprazole magnesium, lansoprazole, omeprazole, or pantoprazole sodium)&#xD;
&#xD;
          -  No concurrent micronutrient supplements or dietary soy products&#xD;
&#xD;
               -  One daily multivitamin allowed&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elisabeth I. Heath, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-1379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weisberg Cancer Treatment Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>March 21, 2006</study_first_submitted>
  <study_first_submitted_qc>March 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2006</study_first_posted>
  <last_update_submitted>January 14, 2014</last_update_submitted>
  <last_update_submitted_qc>January 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Barbara Ann Karmanos Cancer Institute</investigator_affiliation>
    <investigator_full_name>Elisabeth Heath</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>recurrent prostate cancer</keyword>
  <keyword>stage I prostate cancer</keyword>
  <keyword>stage II prostate cancer</keyword>
  <keyword>stage III prostate cancer</keyword>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>3,3'-diindolylmethane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

